This is a preview of subscription content, log in via an institution to check access.
Notes
epidermal growth factor receptor
The study received financial support from Boehringer Ingelheim.
Reference
Yang JC, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology : Jul 2013. Available from: URL: http://dx.doi.org/10.1200/JCO.2012.46.1764
Rights and permissions
About this article
Cite this article
Better symptom control, better QOL with afatinib in NSCLC. PharmacoEcon Outcomes News 683, 10 (2013). https://doi.org/10.1007/s40274-013-0583-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0583-3